Sean Xi Yong Fu，自2024年11月起担任首席执行官，自2024年7月起担任I-Mab董事，此前自2024年7月起担任I-Mab临时首席执行官。在加入I-Mab之前，Sean Fu博士于2024年4月至2024年10月担任bio - x（生命科学公司孵化平台）的运营合伙人。在加入ABio-X之前，Fu博士于2021年6月至2024年2月担任mRNA平台公司RVAC Medicines的联合创始人兼首席执行官。在此之前，Fu博士于2016年至2021年6月担任绿叶制药集团副总裁兼国际研发主管，负责监督波士顿，普林斯顿，德国，瑞士和日本的组织。他还曾担任GeneLeap（绿叶子公司，专注于DNA和RNA治疗）的首席执行官。在加入绿叶制药之前，他于2016年担任新药输送公司Cueport Inc.的总裁。此前，Fu博士于2001年至2016年在Merck & Co.工作，负责研发、业务发展、财务和运营管理。他分别于2000年和2001年获得The Ohio State大学的材料科学与工程硕士和博士学位，并于2010年获得The Wharton School of Pennsylvania大学的工商管理硕士学位。

Sean Xi Yong Fu,has served as Chief Executive Officer since November 2024 and Director of I-Mab since July 2024, having previously served as I-Mab Interim Chief Executive Officer from July 2024. Before joining I-Mab, Dr. Sean Fu served as an Operating Partner of ABio-X, an incubation platform for life sciences companies, from April 2024 to October 2024. Before joining ABio-X, Dr. Fu was co-founder and served as Chief Executive Officer of RVAC Medicines, an mRNA platform company, from June 2021 to February 2024. Prior to that, Dr. Fu served as Group Vice President and Head of International R&D for Luye Pharma from 2016 to June 2021, overseeing organizations in Boston, Princeton, Germany, Switzerland and Japan. He also served as the Chief Executive Officer of GeneLeap, a Luye subsidiary company focused on DNA and RNA therapeutics. Prior to joining Luye Pharma, in 2016 Dr. Fu served as President of Cueport Inc., a novel drug delivery company. Previously, Dr. Fu worked at Merck & Co. from 2001 to 2016, with responsibilities covering R&D, business development, finance and operational management. Dr. Fu earned Master's and Ph.D. degrees in Materials Science and Engineering from The Ohio State University in 2000 and 2001, respectively, and an MBA from the Wharton School of the University of Pennsylvania in 2010.

Kyler Lei，是一位全球资本市场和投资者关系专业人士，在医疗保健、股票研究、企业传播、企业融资和战略方面拥有丰富的经验。Mr. Lei主要负责监督整体财务战略和管理、公司财务和资本市场、公司发展和运营。2022年7月至2025年10月，Mr. Lei在Sino BioPharmaceutical Limited（HKEX：1177）担任副总经理兼资本市场主管，主要负责企业融资和资本市场。在此之前，2021年6月至2022年7月，Mr. Lei在药明康德股份有限公司（上海证券交易所代码：603259，香港交易所代码：2359）担任投资者关系主管，负责投资者关系和财经公关。2020年6月至2021年6月，Mr. Lei在大和证券担任副董事，担任覆盖中国医疗保健行业的首席研究分析师。Mr. Lei还曾于2018年6月至2020年6月期间受雇于麦格理集团，担任股票研究分析师。Mr. Lei于香港科技大学取得生物科技硕士学位，并于香港大学取得经济及金融学士学位。

Kyler Lei,is a global capital markets and investor relations professional with extensive experience in healthcare, equity research, corporate communications, corporate finance and strategy. Mr. Lei is primarily responsible for overseeing the overall financial strategy and management, corporate finance and capital markets, corporate development and operations. From July 2022 to October 2025, Mr. Lei served as deputy general manager and head of capital markets at Sino Biopharmaceutical Limited (HKEX: 1177), where he was primarily responsible for corporate finance and capital markets. Prior to that, from June 2021 to July 2022, Mr. Lei was head of investor relations at WuXi AppTec Co., Ltd. (Shanghai Stock Exchange: 603259, and HKEX: 2359), where he was responsible for investor relations and financial public relations. From June 2020 to June 2021, Mr. Lei was associate director at Daiwa Securities, where he was the lead research analyst covering China healthcare industry. Mr. Lei was also employed by Macquarie Group from June 2018 to June 2020 as an equity research analyst. Mr. Lei obtained his master's degree in biotechnology from Hong Kong University of Science and Technology and his bachelor's degree in economics and finance from the University of Hong Kong.

傅唯，自2018年6月起担任董事，自2024年7月起担任I-Mab董事会主席。傅先生由C-Bridge实体根据I-Mab与其其他各方于2019年7月25日签署的第四份经修订和重述的股东协议任命，并自2014年4月起担任首席执行官。他目前还担任Everest Medicines Limited （HKEX： 1952）和几家私人公司的董事会成员。2011年至2013年，他担任Far East Horizon International（金融服务组织）的投资部门总经理。2010年至2011年，他担任Themes Investment Management Ltd（一家专注于医疗保健和环境业务的私募股权公司）北京办事处的合伙人和主管。2008年至2010年，傅先生担任渣打商业咨询（北京）有限公司私募股权部副总监，主要负责与基础设施项目相关的私募股权投资。他于2005年2月获得新加坡南洋理工大学的电气工程和工商管理学士学位。

Wei Fu,has served as director since June 2018 and Chairman of I-Mab board of directors since July 2024. Mr. Fu was appointed by the C-Bridge entities pursuant to the fourth amended and restated shareholders agreement, dated as of July 25, 2019 between I-Mab and the other parties thereto, and has served as the Chief Executive Officer since April 2014. Mr. Fu currently also serves on the board of Everest Medicines Limited (HKEX: 1952) and several private companies. From 2011 to 2013, Mr. Fu served as the general manager of the investment department at Far East Horizon International, a financial services organization. Mr. Fu served as a partner and the head of the Beijing office of Themes Investment Management Ltd, a private equity firm specializing in healthcare and environmental businesses, from 2010 to 2011. From 2008 to 2010, Mr. Fu worked as an associate director of the private equity department at Standard Chartered Business Consulting (Beijing) Co., Ltd, where he was mainly responsible for private equity investment in relation to infrastructure projects. Mr. Fu received his bachelor's degree in electrical engineering and business administration from Nanyang Technological University in Singapore in February 2005.

Phillip Dennis，自2024年6月起担任首席医疗官。在加入I-Mab之前，Dennis博士于2021年4月至2024年6月期间担任赛诺菲（SNY）肺癌战略副总裁。在加入赛诺菲之前，Dennis博士于2014年至2021年4月在阿斯利康（AZN）担任肺癌战略副总裁和全球临床负责人。在从事制药职业之前，Dennis博士是约翰霍普金斯大学肿瘤学、医学和药理学教授，2012年至2014年担任胸部肿瘤学卓越中心主任。Dennis博士的学术生涯始于1998年至2012年美国国家癌症研究所的转化研究员，并于2006年获得高级研究员的终身职位。Dennis博士在约翰霍普金斯大学完成了内科住院医师和医学肿瘤学研究金，并获得了纽约大学医学院的医学博士和博士学位，这是医学科学家培训计划的一部分。Dennis博士获得了弗吉尼亚大学的本科学位，在那里他是Echols学者。他获得了包括美国国立卫生研究院优异奖在内的多个奖项，并且是美国临床研究学会的当选成员。

Phillip Dennis,has served as Chief Medical Officer since June 2024. Prior to joining I-Mab, Dr. Dennis was Vice President of Lung Cancer Strategy at Sanofi (Nasdaq: SNY) from April 2021 to June 2024. Prior to Sanofi, Dr. Dennis was Vice President of Lung Cancer Strategy and Global Clinical Lead at AstraZeneca (Nasdaq: AZN) from 2014 to April 2021. Prior to his pharmaceutical career, Dr. Dennis was Professor of Oncology, Medicine, and Pharmacology at Johns Hopkins University, where he served as the Director of the Center of Excellence for Thoracic Oncology from 2012 to 2014. Dr. Dennis began his academic career as a translational researcher at the US National Cancer Institute from 1998 to 2012, where he achieved tenure as a Senior Investigator in 2006. Dr. Dennis completed his residency in Internal Medicine and fellowship in Medical Oncology at Johns Hopkins and received his MD and Ph.D. degrees from the New York University School of Medicine as part of the Medical Scientist Training Program. Dr. Dennis received his undergraduate degree from the University of Virginia, where he was an Echols Scholar. He has won several awards including an NIH Merit Award and is an elected member of the American Society for Clinical Investigation.

Sean Cao目前担任CBC Group（原C-Bridge Capital）运营合伙人，该职位自2024年1月起担任。Dr. Cao于2021年5月与他人共同创立ABio-X Holdings，并担任首席执行官。Dr. Cao还在2021年5月至2023年6月期间共同创立并担任Ensem Therapeutics的首任首席执行官。此外，Dr. Cao还与他人共同创立并目前担任RVAC医药和翡翠医药的董事会成员。2017年，Dr. Cao与人共同创立了Everest Medicines，并担任其首席执行官至2020年。在打造Everest Medicines的同时，Dr. Cao还与其科学联合创始人在美国孵化了Nikang Therapeutics，从成立到2020年，他一直担任首席执行官，并在2021年9月之前担任董事会主席。Dr. Cao还于2016年成立至2018年期间担任I-Mab Biopharma的首席商务官。在担任I-Mab Biopharma首席商务官之前，Dr. Cao曾担任先声药业（“先声药业”）全球业务发展副总裁。Dr. Cao还是先声药业全资子公司美国先声药业的总裁兼董事。在此之前，Dr. Cao是赛诺菲的替代伙伴关系、评估与专业知识高级总监。在加入赛诺菲之前，Dr. Cao是New Leaf Venture Partners的合伙人。Dr. Cao在加入New Leaf Venture Partners之前曾在制药和诊断行业工作了几年，先是在安万特，然后在强生。Dr. Cao获得弗吉尼亚大学微生物学博士学位、宾夕法尼亚大学沃顿商学院荣誉MBA学位、南开大学微生物学理学学士学位。

Sean Cao currently serves as Operating Partner of CBC Group (formerly C-Bridge Capital), a position he has held since January 2024. Dr. Cao co-founded ABio-X Holdings in May 2021 and serves as the company's Chief Executive Officer. Dr. Cao also co-founded and served as the first Chief Executive Officer of Ensem Therapeutics from May 2021 to June 2023. In addition, Dr. Cao co-founded and currently serves on the board of directors of RVAC Medicines and Jadeite Medicines. In 2017, Dr. Cao co-founded Everest Medicines and served as its Chief Executive Officer until 2020. While building Everest Medicines, Dr. Cao also incubated NiKang Therapeutics with its scientific co-founders in the United States, where he served as the Chief Executive Officer from its inception until 2020, and the chairman of its board of directors until September 2021. Dr. Cao also served as the Chief Business Officer for I-Mab Biopharma from the company's inception in 2016 until 2018. Prior to his tenure as Chief Business Officer of I-Mab Biopharma, Dr. Cao was VP of Global Business Development at Simcere Pharmaceutical Group ("Simcere"). Dr. Cao was also the President and director at Simcere of America, a wholly owned subsidiary of Simcere. Prior to that, Dr. Cao was the Senior Director of Alternative Partnership, Evaluation & Expertise at Sanofi. Before Sanofi, Dr. Cao was an associate at New Leaf Venture Partners. Dr. Cao worked in the pharmaceutical and diagnostic industries for several years before joining New Leaf Venture Partners, first at Aventis, then at Johnson & Johnson. Dr. Cao received a Ph.D. in Microbiology from the University of Virginia, an MBA with honors from the Wharton School of the University of Pennsylvania, and a B.Sc. in Microbiology from Nankai University.

Sean Xi Yong Fu，自2024年11月起担任首席执行官，自2024年7月起担任I-Mab董事，此前自2024年7月起担任I-Mab临时首席执行官。在加入I-Mab之前，Sean Fu博士于2024年4月至2024年10月担任bio - x（生命科学公司孵化平台）的运营合伙人。在加入ABio-X之前，Fu博士于2021年6月至2024年2月担任mRNA平台公司RVAC Medicines的联合创始人兼首席执行官。在此之前，Fu博士于2016年至2021年6月担任绿叶制药集团副总裁兼国际研发主管，负责监督波士顿，普林斯顿，德国，瑞士和日本的组织。他还曾担任GeneLeap（绿叶子公司，专注于DNA和RNA治疗）的首席执行官。在加入绿叶制药之前，他于2016年担任新药输送公司Cueport Inc.的总裁。此前，Fu博士于2001年至2016年在Merck & Co.工作，负责研发、业务发展、财务和运营管理。他分别于2000年和2001年获得The Ohio State大学的材料科学与工程硕士和博士学位，并于2010年获得The Wharton School of Pennsylvania大学的工商管理硕士学位。

Sean Xi Yong Fu,has served as Chief Executive Officer since November 2024 and Director of I-Mab since July 2024, having previously served as I-Mab Interim Chief Executive Officer from July 2024. Before joining I-Mab, Dr. Sean Fu served as an Operating Partner of ABio-X, an incubation platform for life sciences companies, from April 2024 to October 2024. Before joining ABio-X, Dr. Fu was co-founder and served as Chief Executive Officer of RVAC Medicines, an mRNA platform company, from June 2021 to February 2024. Prior to that, Dr. Fu served as Group Vice President and Head of International R&D for Luye Pharma from 2016 to June 2021, overseeing organizations in Boston, Princeton, Germany, Switzerland and Japan. He also served as the Chief Executive Officer of GeneLeap, a Luye subsidiary company focused on DNA and RNA therapeutics. Prior to joining Luye Pharma, in 2016 Dr. Fu served as President of Cueport Inc., a novel drug delivery company. Previously, Dr. Fu worked at Merck & Co. from 2001 to 2016, with responsibilities covering R&D, business development, finance and operational management. Dr. Fu earned Master's and Ph.D. degrees in Materials Science and Engineering from The Ohio State University in 2000 and 2001, respectively, and an MBA from the Wharton School of the University of Pennsylvania in 2010.

欧振国，是GT Healthcare Group（私人股本基金，专注于跨境医疗投资）的现任合伙人，以及TUS-Lifetree Capital Partners公司（专注于中国医疗私人股本投资）的合伙人。他也是Simcere Pharmaceutical Group（中国领先的制药公司）的顾问，也是China Nepstar Chain Drugstore Ltd.（NYSE：NPD）的董事会、审计委员会和薪酬委员会的成员。此外，他也担任由香港特别行政区政府创新及科技基金（the Innovation and Technology Fund of the Hong Kong SAR Government）的企业家的支持计划（ESS课程）的上诉委员。从2013年到2015年，他曾担任Ally Bridge Group（跨境生物技术投资基金，专注于从美国到中国的前沿技术）的风险合伙人。他也曾担任Deutsche Bank Group的亚洲医疗投资银行主管，建议该地区医疗上市和并购。此前，他曾担任JAFCO Asia Investment Group的执行董事，负责中国的医疗投资（2008年至2010年），以及Morningside Group的投资董事，负责亚洲的医疗投资（从2000年到2005年）。1995年至1999年，他曾任职KPMG公司、KPMG Corporate Finance Ltd.，负责地区并购交易和金融咨询服务。

Chun Kwok Alan Au,has served as director since January 2020. Mr. Au is the founder of GT Healthcare, a private equity fund focusing on cross border healthcare investments and has served as a managing partner since September 2015. Mr. Au has served as a member of the board of directors, and the chairman of the audit committee of CSPC Pharmaceutical Group (HKEX: 1093), a leading pharmaceutical group in China, since January 2021. Mr. Au also has served as a panel member for the Entrepreneur Support Scheme (ESS Program) of the Innovation and Technology Fund of the Hong Kong SAR Government from 2014 to 2022. Mr. Au was an advisor to Simcere Pharmaceutical Group, a leading pharmaceutical company in China (previously listed on NYSE: SCR, privatized in December 2013, when Mr. Au served as chairman of the special committee on the board of directors). Mr. Au was also a member of the board of China Nepstar Chain Drugstore Ltd. (NYSE: NPD, privatized in September 2016) from 2013 to 2016. He was also a member of the board of Cellular BioMedicine Group (Nasdaq: CBMG, privatized in February 2021), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies from 2014 to February 2021. Prior to these, Mr. Au served as the head of the Asia Healthcare Investment Banking of Deutsche Bank Group, advising healthcare IPOs and M&A in the region from 2011 to 2012. Prior to that, Mr. Au served as an investment director at JAFCO Asia Investment Group, responsible for healthcare investments in China from 2008 to 2010. Mr. Au worked at Morningside Group as a director in charge of healthcare investments in Asia from 2000 to 2005. Mr. Au received his bachelor's degree in psychology from Chinese University of Hong Kong in 1995 and his master's degree in management from Columbia Business School in New York in 2007. Mr. Au is a certified public accountant (CPA) in the United States and a chartered financial analyst (CFA). He is a member of the Hong Kong Institute of Financial Analysts and member of the American Institute of Certified Public Accountants.

傅唯，自2018年6月起担任董事，自2024年7月起担任I-Mab董事会主席。傅先生由C-Bridge实体根据I-Mab与其其他各方于2019年7月25日签署的第四份经修订和重述的股东协议任命，并自2014年4月起担任首席执行官。他目前还担任Everest Medicines Limited （HKEX： 1952）和几家私人公司的董事会成员。2011年至2013年，他担任Far East Horizon International（金融服务组织）的投资部门总经理。2010年至2011年，他担任Themes Investment Management Ltd（一家专注于医疗保健和环境业务的私募股权公司）北京办事处的合伙人和主管。2008年至2010年，傅先生担任渣打商业咨询（北京）有限公司私募股权部副总监，主要负责与基础设施项目相关的私募股权投资。他于2005年2月获得新加坡南洋理工大学的电气工程和工商管理学士学位。

Wei Fu,has served as director since June 2018 and Chairman of I-Mab board of directors since July 2024. Mr. Fu was appointed by the C-Bridge entities pursuant to the fourth amended and restated shareholders agreement, dated as of July 25, 2019 between I-Mab and the other parties thereto, and has served as the Chief Executive Officer since April 2014. Mr. Fu currently also serves on the board of Everest Medicines Limited (HKEX: 1952) and several private companies. From 2011 to 2013, Mr. Fu served as the general manager of the investment department at Far East Horizon International, a financial services organization. Mr. Fu served as a partner and the head of the Beijing office of Themes Investment Management Ltd, a private equity firm specializing in healthcare and environmental businesses, from 2010 to 2011. From 2008 to 2010, Mr. Fu worked as an associate director of the private equity department at Standard Chartered Business Consulting (Beijing) Co., Ltd, where he was mainly responsible for private equity investment in relation to infrastructure projects. Mr. Fu received his bachelor's degree in electrical engineering and business administration from Nanyang Technological University in Singapore in February 2005.

Robert Lenz，自2023年9月起担任Neumora Therapeutics, Inc.研发主管。从2012年11月到2023年9月，Lenz博士在Amgen（一家公共生物制药公司）任职，在那里他最近担任全球发展高级副总裁（2020年5月至2023年9月），以及副总裁，设计和分析中心负责人，炎症，神经学和肾脏病发展特许经营负责人（2018年11月至2020年5月）。此前，从2004年6月到2012年11月，他在雅培实验室的临床开发部门担任职务，最近从2011年1月到2012年11月担任神经科学、麻醉、精神病学发展部门副总裁。他持有Maryland大学的医学博士和博士学位，研究重点是神经药理学。他在加州大学洛杉矶分校完成了神经学实习。

Robert Lenz,has served as Neumora Therapeutics, Inc. Head of Research & Development since September 2023. From November 2012 to September 2023, Dr. Lenz was at Amgen, a public biopharmaceutical company, where he most recently served as Senior Vice President, Global Development from May 2020 to September 2023 and as Vice President, head of Center for Design and Analysis, Inflammation, Neurology and Nephrology Development Franchise Head from November 2018 to May 2020. Previously, Dr. Lenz held roles within clinical development at Abbott Laboratories from June 2004 to November 2012, most recently serving as Divisional Vice President, Neuroscience, Anesthesia, Psychiatry Development from January 2011 to November 2012. Dr. Lenz holds an M.D. and a Ph.D. from the University of Maryland, with a research focus in Neuropharmacology. He completed his residency in Neurology at the University of California, Los Angeles.

Sean Cao目前担任CBC Group（原C-Bridge Capital）运营合伙人，该职位自2024年1月起担任。Dr. Cao于2021年5月与他人共同创立ABio-X Holdings，并担任首席执行官。Dr. Cao还在2021年5月至2023年6月期间共同创立并担任Ensem Therapeutics的首任首席执行官。此外，Dr. Cao还与他人共同创立并目前担任RVAC医药和翡翠医药的董事会成员。2017年，Dr. Cao与人共同创立了Everest Medicines，并担任其首席执行官至2020年。在打造Everest Medicines的同时，Dr. Cao还与其科学联合创始人在美国孵化了Nikang Therapeutics，从成立到2020年，他一直担任首席执行官，并在2021年9月之前担任董事会主席。Dr. Cao还于2016年成立至2018年期间担任I-Mab Biopharma的首席商务官。在担任I-Mab Biopharma首席商务官之前，Dr. Cao曾担任先声药业（“先声药业”）全球业务发展副总裁。Dr. Cao还是先声药业全资子公司美国先声药业的总裁兼董事。在此之前，Dr. Cao是赛诺菲的替代伙伴关系、评估与专业知识高级总监。在加入赛诺菲之前，Dr. Cao是New Leaf Venture Partners的合伙人。Dr. Cao在加入New Leaf Venture Partners之前曾在制药和诊断行业工作了几年，先是在安万特，然后在强生。Dr. Cao获得弗吉尼亚大学微生物学博士学位、宾夕法尼亚大学沃顿商学院荣誉MBA学位、南开大学微生物学理学学士学位。

Sean Cao currently serves as Operating Partner of CBC Group (formerly C-Bridge Capital), a position he has held since January 2024. Dr. Cao co-founded ABio-X Holdings in May 2021 and serves as the company's Chief Executive Officer. Dr. Cao also co-founded and served as the first Chief Executive Officer of Ensem Therapeutics from May 2021 to June 2023. In addition, Dr. Cao co-founded and currently serves on the board of directors of RVAC Medicines and Jadeite Medicines. In 2017, Dr. Cao co-founded Everest Medicines and served as its Chief Executive Officer until 2020. While building Everest Medicines, Dr. Cao also incubated NiKang Therapeutics with its scientific co-founders in the United States, where he served as the Chief Executive Officer from its inception until 2020, and the chairman of its board of directors until September 2021. Dr. Cao also served as the Chief Business Officer for I-Mab Biopharma from the company's inception in 2016 until 2018. Prior to his tenure as Chief Business Officer of I-Mab Biopharma, Dr. Cao was VP of Global Business Development at Simcere Pharmaceutical Group ("Simcere"). Dr. Cao was also the President and director at Simcere of America, a wholly owned subsidiary of Simcere. Prior to that, Dr. Cao was the Senior Director of Alternative Partnership, Evaluation & Expertise at Sanofi. Before Sanofi, Dr. Cao was an associate at New Leaf Venture Partners. Dr. Cao worked in the pharmaceutical and diagnostic industries for several years before joining New Leaf Venture Partners, first at Aventis, then at Johnson & Johnson. Dr. Cao received a Ph.D. in Microbiology from the University of Virginia, an MBA with honors from the Wharton School of the University of Pennsylvania, and a B.Sc. in Microbiology from Nankai University.

Xin Liu，现任Hony Capital医疗健康集团投资总监，该职位自2023年8月起担任。在此之前，2019年至2022年9月，Ms. Liu担任CCBPE投资副总裁。2016年至2018年，她在复星集团担任医疗健康投资集团投资经理。Ms. Liu在哈里斯堡大学获得工学、企业信息系统工程和管理硕士学位，在麻省理工学院获得金融硕士学位。Ms. Liu在圣路易斯华盛顿大学获得金融和数学本科学位。

Xin Liu,currently serves as Investment Director, Healthcare Group of Hony Capital, a position she has held since August 2023. Prior to that, from 2019 to September 2022, Ms. Liu was Vice President of Investment at CCBPE. From 2016 to 2018 she served as Investment Manager, Healthcare Investment Group at the Fosun Group. Ms. Liu earned a Master of Engineering, Enterprise Information System Engineering and Management from Harrisburg University, and a Master, Finance from the Massachusetts Institute of Technology. Ms. Liu received her undergraduate degree in finance and mathematics from Washington University in St. Louis.

杨嘉宏，现任亿航智能控股有限公司董事，自2023年9月1日起，被任命为亿航智能新的首席财务官，同时保留董事职务。在被任命为首席财务官之前，杨先生自2019年12月起担任亿航智能董事会的独立董事、审计委员会主席和薪酬委员会成员。2007年至2023年，杨先生曾在多家公司担任首席财务官，包括途牛公司（纳斯达克：TOUR）、中国电子商务当当网公司、航美传媒集团公司。2004年至2007年，杨先生担任Rock Mobile Corporation的首席执行官。1999年至2004年，杨先生担任CellStar Asia Corporation的亚太区首席财务官。在此之前，杨先生于1992年至1999年在高盛（亚洲）有限公司、雷曼兄弟亚洲有限公司和摩根斯坦利亚洲有限公司担任高级银行家。目前，杨先生还担任天境生物（纳斯达克：IMAB）、爱奇艺公司（纳斯达克：IQ）、同程旅游控股有限公司（港交所：0780）、老虎证券（纳斯达克：TIGR）和怪兽充电（纳斯达克：EM）的独立董事。杨先生在加州大学洛杉矶分校获得工商管理硕士学位。于2022年6月6日获委任为同程旅行控股有限公司审核委员会主席、环境、社会及管治委员会主席。

Conor Chia hung Yang,has served as independent director since June 2023. Mr. Yang has been the chief financial officer of EHang Holdings Limited (Nasdaq: EH) since September 2023. From 2007 to 2023, Mr. Yang served in several chief financial officer positions, including Tuniu Corporation (Nasdaq: TOUR), E-Commerce China Dangdang Inc. and AirMedia Group Inc. Mr. Yang was the chief executive officer of Rock Mobile Corporation from 2004 to 2007, and the chief financial officer of the Asia Pacific region for CellStar Asia Corporation from 1999 to 2004. Prior to that, Mr. Yang was a senior banker at Goldman Sachs (Asia) L.L.C., Lehman Brothers Asia Limited and Morgan Stanley Asia Limited from 1992 to 1999. Mr. Yang currently also serves as an independent director of I-Mab (Nasdaq: IMAB), iQIYI, Inc. (Nasdaq: IQ), Tongcheng Travel Holdings Limited (HKEx: 0780) and UP Fintech Holding Ltd. (Nasdaq: TIGR). Mr. Yang received his master's degree in business administration from the University of California, Los Angeles.